Citigroup Maintains Buy on Eiger BioPharmaceuticals, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a 'Buy' rating on Eiger BioPharmaceuticals but lowers the price target from $4 to $3.
August 29, 2023 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a 'Buy' rating on Eiger BioPharmaceuticals but lowers the price target from $4 to $3.
The news is directly related to Eiger BioPharmaceuticals. While the 'Buy' rating is maintained, the lowering of the price target might indicate a potential decrease in the short-term stock price. However, the overall impact is neutral as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100